MEDI0639: A novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1650-1660

  Jenkins, David W ^a,d   Ross, Sarah ^a   Veldman Jones, Margaret ^a   Foltz, Ian N ^b   Clavette, Brandon C ^b   Manchulenko, Kathy ^c   Eberlein, Cath ^a   Kendrew, Jane ^a   Petteruti, Philip ^a   Cho, Song ^c   Damschroder, Melissa ^c   Peng, Li ^c   Baker, Dawn ^a   Smith, Neil R ^a   Weir, Hazel M ^a   Blakey, David C ^a   Bedian, Vahe ^a   Barry, Simon T ^a  

^a ASTRAZENECA   (United Kingdom)

^b Amgen   (Canada)

^c MEDIMMUNE   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY MEDI0639; BINDING PROTEIN; DELTA LIKE LIGAND 4; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; ENDOTHELIAL CELLS; EPITOPE MAPPING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84864877183     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-1027     Document Type: Article

References (35)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6. (Pubitemid 29291335)
2. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
3. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-89. (Pubitemid 44268213)
4. Karsan A. The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol 2005;83:14-23. (Pubitemid 40754771)
5. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. Bioessays 2004;26:225-34. (Pubitemid 38325664)
6. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, et al. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 2004;18:2474-8. (Pubitemid 39362889)
7. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 2004;101:15949-54. (Pubitemid 39507907)
8. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004;18:2469-73. (Pubitemid 39362888)
9. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9. (Pubitemid 26102719)
10. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42. (Pubitemid 26102720)
11. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69:135-44. (Pubitemid 33755062)
12. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65:8690-7. (Pubitemid 41377356)
13. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 2010;16:848-56.
14. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006;12:4836-44. (Pubitemid 44338568)
15. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 2010;176:2019-28.
16. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53. (Pubitemid 350248550)
17. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
18. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80. (Pubitemid 46279716)
19. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7. (Pubitemid 46018529)
20. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 2007;283:106-20; discussion 121-5, 238-41.
21. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007;109:4753-60. (Pubitemid 46827768)
22. Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, et al. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol Cancer Ther 2011;10:770-83.
23. Yoneya T, Tahara T, Nagao K, Yamada Y, Yamamoto T, Osawa M, et al. Molecular cloning of delta-4, a new mouse and human Notch ligand. J Biochem 2001;129:27-34. (Pubitemid 32150479)
24. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002;3:688-94.
25. Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010;13:337-47.
26. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998;393:382-6. (Pubitemid 28269713)
27. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010;116:4025-33.
28. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998;143:1341-52. (Pubitemid 28559834)
29. Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007;13:389-95. (Pubitemid 47385383)
30. Phng LK, Potente M, Leslie JD, Babbage J, Nyqvist D, Lobov I, et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell 2009;16:70-82.
31. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006;107:931-9. (Pubitemid 43156289)
32. Harrington LS, Sainson RC, Williams CK, Taylor JM, Shi W, Li JL, et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 2008;75:144-54. (Pubitemid 351249857)
33. Alajati A, Laib AM, Weber H, Boos AM, Bartol A, Ikenberg K, et al. Spheroid-based engineering of a human vasculature in mice. Nat Methods 2008;5:439-45. (Pubitemid 351619103)
34. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-notch signaling mediates tumor resistance to Anti-VEGF therapy in vivo. Cancer Res 2011;71:6073-83.
35. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood 2011;117:719-26.